FAQ

Yes — quite strongly, actually.

Clinical trials (like SURPASS and SURMOUNT) have shown that tirzepatide doesn’t just reduce overall body weight; it preferentially targets visceral adipose tissue — the fat wrapped around internal organs that drives insulin resistance and inflammation.

MRI and CT imaging data from those studies found that people taking tirzepatide lost a higher percentage of visceral fat compared to subcutaneous fat. This is part of why improvements in insulin sensitivity, blood pressure, and lipid levels tend to be so pronounced even before total weight loss catches up.

In plain terms: tirzepatide helps your body burn the dangerous, “deep” fat first — the one that matters most for metabolic health.

Here are a few clinical-trial / study links and papers about tirzepatide’s effects on visceral fat / body fat distribution:

• Effect of tirzepatide versus insulin degludec on liver fat content and abdominal fat (a substudy of SURPASS-3) — The Lancet / Landia article The Lancet

• Body composition changes during weight reduction with tirzepatide (SURMOUNT-1) — via PMC / open access article PMC+1

• Tirzepatide and cardiometabolic parameters in obesity / SURPASS-3 MRI sub-study — discusses visceral adipose tissue reductions PMC+1

• Effect of Tirzepatide on Brown Adipose Tissue in Obesity (TABFAT) — the trial registration entry on ClinicalTrials.gov, NCT06893211 ClinicalTrials.gov

• Protocol paper for the TABFAT study (“Effect of tirzepatide-induced weight loss on adipose tissue in obesity”) in Trials journal BioMed Central